secwatch / observer
8-K filed April 5, 2023, 7:59 PM ET ticker NUTX CIK 0001479681
leadership confidence high sentiment neutral materiality 0.40

Nutex Health board: Dr. Young departs after one-year term, Dr. Stites elected

Nutex Health Inc.

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Dr. Matthew Young

Director
NUTX · Nutex Health Inc.
Effective
2023-03-31
Successor
Dr. Danniel Stites
Filed
April 5, 2023, 7:59 PM ET
On March 31, 2023, Dr. Matthew Young informed the Board of Directors (the “Board”) of Nutex Health Inc. (the “Company”) that he had decided to depart from the Board at the end of his one year term commitment which had commenced on April 1, 2022.
Appointed

Dr. Danniel Stites

Director
NUTX · Nutex Health Inc.
Effective
2023-04-01
Filed
April 5, 2023, 7:59 PM ET
On April 1, 2023, the Board elected Dr. Danniel Stites, age 42, as a member of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Matthew Young departed as Director at Nutex Health Inc..

Action
departed
Role
Director
Exact text from the filing
On March 31, 2023, Dr. Matthew Young informed the Board of Directors (the “Board”) of Nutex Health Inc. (the “Company”) that he had decided to depart from the Board at the end of his one year term commitment which had commenced on April 1, 2022.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Danniel Stites was elected as Director at Nutex Health Inc..

Action
elected
Role
Director
Exact text from the filing
On April 1, 2023, the Board elected Dr. Danniel Stites, age 42, as a member of the Board.
View on SEC.gov

Nutex Health Inc. filing history →

Source: SEC EDGAR
accession 0001104659-23-042250
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.